已收盤 10-30 16:00:00 美东时间
0.000
0.00%
INVO Fertility shares are trading lower after the company reported a year-over-...
08-16 01:53
INVO Fertility ( ($IVF) ) has provided an update. On July 28, 2025, an institut...
08-02 04:53
转自:证券时报 人民财讯8月1日电,艾伯维近日宣布,upadacitinib(RINVOQ®)治疗斑秃的UP-AA临床研究中两项关键性研究中的第一项取得积极结果...
08-01 13:01
AbbVie posted $15.42 billion in Q2 revenue, topping estimates, with strong immunology and neuroscience growth, while full-year earnings guidance was raised.
07-31 23:18
In Study 2 of the pivotal Phase 3 UP-AA clinical program, upadacitinib (RINVOQ®) achieved the primary endpoint, demonstrating that 44.6% and 54.3% of patients with severe alopecia areata treated with upadacitinib 15
07-30 20:34
UNHNVDASOFINVOAMDGOOGLGLDTSLASPOTPYPLData from https://swaggystocks.com/dashboard/wallstreetbets/ticker-sentiment
07-29 21:16
INVO Fertility (NASDAQ:IVF) will effect a 1-for-3 reverse split of its issued and outstanding and authorized common stock effective as of 12:01 a.m. Eastern Time on July 21, 2025. Commencing with the ...
07-17 20:37
INVO Fertility, Inc. ("INVO") (NASDAQ:IVF), a healthcare company focused on the fertility market, announced today that it will effect a 1-for-3 reverse split of its issued and outstanding and authorized common stock
07-17 20:02
INVO Fertility, Inc. announced a 1-for-3 reverse stock split effective July 21, 2025, to comply with Nasdaq’s $1.00 minimum bid price requirement. After the split, the company will have approximately 928,272 shares outstanding, with the trading symbol "IVF" remaining unchanged. The company focuses on expanding fertility services through its INVO_centers and IVF clinics, utilizing the INVOcell medical device for in vivo fertilization.
07-17 12:00
(转自:国金证券研究所) 摘要 核心观点: 政策、成本、技术三者齐发力,城市NOA渗透率有望提升到15%,高速NOA有望渗透率超过60%。政策端...
07-07 07:32